NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Aradigm, a benefits platform for cell and gene therapies, launched from stealth today to make life-saving medicines affordable and accessible at a national scale. The company is debuting with a $20 million Series A funding round led by Frist Cressey Ventures, with participation from Andreessen Horowitz and Morgan Health, a division of JPMorganChase focused on employer-sponsored health care. This milestone follows Aradigm's $5 million seed round led by Andreessen Horowitz in 2024.

Cell and gene therapies (CGTs) have the potential to treat once-untreatable diseases, but some therapies exceed $3 million per treatment, and costs vary up to 200 percent between payers. A public benefit corporation, Aradigm aims to create affordable, sustainable access to CGTs by improving predictability for both payers and health care providers and to bring together all stakeholders in the cell and gene therapy ecosystem, payers, employers, providers, manufacturers, and, most importantly, patients, in a unique financial and delivery model.

"Cell and gene therapies have extraordinary potential to transform lives, but the fragmented way we pay for and deliver care in the U.S. threatens access to them," said Dr. William Shrank, CEO and Co-Founder of Aradigm, an internal medicine physician and former researcher at Harvard Medical School whose career has included leadership positions in the federal government and at large health plans. "What we have built is a new kind of payment and delivery model that breaks down barriers to these life-saving therapies."

Aradigm's platform applies a cost-plus, transparent pricing model to manage high-cost CGTs. By pooling risk, standardizing reimbursement, and passing any unused premium savings back ...